Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TBI-1301 in NY-ESO-1 Positive Solid Tumors
NCT02366546Phase 1Unknown
- Sponsor
- Mie University
- Start
- Mar 2015
- Primary completion
- Sep 2018
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-NY-ESO-1 TCR-T in solid tumor (4 arms), sponsored by Mie University. Primary endpoints: Incidence and grade of adverse events (CTCAE) at 4 weeks, Appearance of replication competent retrovirus by PCR at 4 weeks and 2 more. Status: unknown.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02366546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366546.